The UK government has recently announced that, by September 2019, boys aged 12 to 13 years will be given the human papillomavirus (HPV) vaccine, a vaccine that has been available to girls in the UK for the past ten years. There has been documented evidence that the HPV vaccine has caused more injuries than any other vaccination in history. Despite this evidence, however, the HPV vaccination has continued to be hailed a success by the pharmaceutical industry and governments alike. According to the MHRA, the adverse event reporting system in the UK, there have been a total of 9,119 reports of adverse reactions reported in the UK since the vaccine was launched in 2008. These reports equate to 23,882 different ailments and include a total of 8 deaths. The UK’s decision to include boys into the equation has alarmed many parents whose daughters have already been injured by the vaccine.
Is the European Medical Agency Experimenting on Babies with the Meningitis Vaccine Only Approved for Age 10 and Above?
In 2016, we published an article on the dangers of the meningitis B vaccination, Bexsero, titled, Are Ineffective New Meningitis B Vaccines Causing Harm to Children? At the time of publication, according to the FDA product information leaflet, the vaccine had in fact only been approved for children over the age of ten. Despite this fact however, in the UK, the meningitis B vaccine Bexsero is being administered to infants as young as 2 months, despite the fact that we could find no evidence to support that this vaccine was safe to be administered to babies. It has been brought to our attention that there are in fact two product information leaflets on the same vaccination. However, what is different about the second product information leaflet, published on January 14, 2015, by the European Medical Agency (EMA) is that the information that it provides, is the polar opposite, of the information provided by the FDA. Is the UK government conducting clinical trials on infants, and if they are, then are parents aware of this fact?